Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]
Awaiting development
Reference number: GID-TA11639
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during early March 2026 when we will write to you about how you can get involved.